AGP Dialogue national : le président Oligui Nguema échange avec les membres du bureau AGP Gabon : Bientôt un recensement des biens de l’Etat AGP Coopération Gabon-France : un forum économique en perspective APS SENEGAL-PRESIDENTIELLE / Bassirou Diomaye Faye reçu en audience par Macky Sall MAP Afrique du Sud: Zuma exclu des prochaines élections (Commission électorale) MAP La CAF annonce les dates des finales de la Ligue des Champions et de la Coupe de la Confédération MAP Afrique du Sud: 45 morts dans un accident d’autocar au Limpopo APS SENEGAL-ITALIE-TRANSPORTS / ITA Airways va inaugurer en juillet une ligne Rome-Dakar APS SENEGAL-ENVIRONNEMENT / Bonne amélioration des taux d’accès à l’eau et à l’assainissement (expert) ANP Signature de convention entre le Niger et la Société WAPCO Niger pour un programme de formation de talents à Southwest Petroleum University de Chine

FDA/Cuba discuss production of COVID-19 vaccine


  12 Février      61        Santé (15315),

 

Accra, Feb. 12, GNA- Mrs Delese Darko, Chief Executive Officer, Food and Drugs Authority (FDA), has met with Mr Pedro Luis Despaigne Gonzalez, the Cuban Ambassador to Ghana, to discuss progress on the development of Cuba’s Covid-19 vaccine.

A statement issued by the FDA in Accra on Thursday, explained that the meeting followed an earlier one held in November 2020, where the Centre for State Control of Drugs and Medical Devices (CECMED) of the Ministry of Public Health of the Republic of Cuba (MINSAP), signed a Memorandum of Understanding with the FDA, to strengthen bilateral relations and cooperation in the area of health promotion.

It said the present meeting, which was at the request of the Ambassador, was therefore to brief Ghana’s FDA on the status of clinical trials being conducted in Cuba on four Covid-19 candidate vaccines, with each at different phases of clinical development.

According to Mr Gonzalez, the COVID-19 vaccine, “Soberana 02”, was Cuba’s most advanced candidate against the COVID-19 virus, which had currently passed Phase I trials in Cuba.

He indicated that Phase II trials had also been carried out on 910 patients, while Phase III trials would commence in February 2021.

Mr Gonzalez again said Cuba intended to offer the transfer of technology through an agreement with the Ghanaian Pharmaceutical Industry for the supply of the active pharmaceutical ingredients for the formulation, production and packaging of the vaccine in Ghana.

According to the statement, Mr Gonzalez had stated that countries like India, Vietnam, Iran, Venezuela and Pakistan had also expressed interest in acquiring the Soberana 02 vaccine.

Mrs. Darko on her part had expressed gratitude to the people and Government of Cuba for their continued solidarity, and pledged the continued support of the FDA in the sharing of its experience as a Maturity Level three regulatory agency of the World Health Organization (WHO).

She further expressed her utmost appreciation for the intended technological transfer support from Cuba, stressing that the meeting presented an opportunity to render support, build capacity, further develop and challenge the local pharmaceutical industry (allopathic and herbal).

She said through the relationship, the pharmaceutical industry would make advances in promoting health, thus improving the health standards of the Ghanaian.

Present at the meeting were Mr. Seth Seneake, the Deputy Chief Executive Officer for Health Products and Technologies Division, Mrs Yvonne Nkrumah, the Deputy CEO for Corporate Services, and Mrs Mercy Mintah Gyampoh, the Pharmaceutical liaison for the Republic of Cuba in Ghana.

Dans la même catégorie